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Background. Rates and risk factors for cytomegalovirus (CMV) prophylaxis breakthrough and discontinuation were investigated, 
given uncertainty regarding optimal dosing for CMV primary (val)ganciclovir prophylaxis after solid organ transplantation (SOT).
Methods. Recipients transplanted from 2012 to 2016 and initiated on primary prophylaxis were followed until 90 days post-
transplantation. A (val)ganciclovir prophylaxis score for each patient per day was calculated during the follow-up time (FUT; score 
of 100 corresponding to manufacturers’ recommended dose for a given estimated glomerular filtration rate [eGFR]). Cox models 
were used to estimate hazard ratios (HRs), adjusted for relevant risk factors.
Results. Of 585 SOTs (311 kidney, 117 liver, 106 lung, 51 heart) included, 38/585 (6.5%) experienced prophylaxis breakthrough 
and 35/585 (6.0%) discontinued prophylaxis for other reasons. CMV IgG donor+/receipient- mismatch (adjusted HR [aHR], 5.37; 
95% confidence interval [CI], 2.63 to 10.98; P < 0.001) and increasing % FUT with a prophylaxis score <90 (aHR, 1.16; 95% CI, 1.04 
to 1.29; P = .01 per 10% longer FUT w/ score <90) were associated with an increased risk of breakthrough. Lung recipients were at a 
significantly increased risk of premature prophylaxis discontinuation (aHR, 20.2 vs kidney; 95% CI, 3.34 to 121.9; P = .001), mainly 
due to liver or myelotoxicity.
Conclusions. Recipients of eGFR-adjusted prophylaxis doses below those recommended by manufacturers were at an increased 
risk of prophylaxis breakthrough, emphasizing the importance of accurate dose adjustment according to the latest eGFR and the 
need for novel, less toxic agents.
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Infection with cytomegalovirus (CMV) frequently complicates 
the course after solid organ transplantation (SOT), and if left 
untreated, asymptomatic CMV DNAemia can in some cases 
progress to CMV disease with poorer clinical outcomes [1, 
2]. To prevent progression to CMV disease in SOT recipients, 
most transplantation centers administer universal prophylaxis 
with valganciclovir or ganciclovir after transplantation [3]. 
However, the optimal dosage and duration of universal pro-
phylaxis are currently debated [4, 5]. Despite being consider-
ably less nephrotoxic than the second-line drugs with activity 
against CMV, namely foscarnet and cidofovir, (val)ganciclovir 
may still induce other treatment-limiting side effects such as 
myelosuppression, leading to early cessation of prophylaxis 
[2, 3, 6–8]. In such patients, it could potentially be benefi-
cial to administer lower dosages of prophylaxis [4]. On the 
other hand, some patients may experience CMV DNAemia 
breakthrough during active administration of prophylaxis, es-
pecially if the recipient is at risk of primary CMV infection 
from the donor (CMV IgG donor [D]+/recipient [R]-) [9, 
10]. Although current guidelines recommend valganciclovir 
900 mg daily (adjusted for renal function) for universal pro-
phylaxis [8, 10], some studies have demonstrated an equiva-
lent efficacy of a dose reduction to 450 mg/d [2, 3, 6, 11, 12]. 
At present, the optimal dose still remains unclear, particularly 
with regards to type of SOT [3]. The aim of the current study 
was to investigate if, and to what extent, different dosages of 
(val)ganciclovir prophylaxis affect the risk of experiencing 
prophylactic breakthrough during active administration of 
prophylaxis. Furthermore, we aimed to identify reasons and 
risk factors for premature prophylaxis discontinuation.
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METHODS
Patients
The Management of Post-Transplant Infections in Collaborating 
Hospitals (MATCH) program was initiated in 2011 with the 
goal of serving as a collaborative platform between individual 
transplant units and the Infectious Disease Department at 
Rigshospitalet, University Hospital Copenhagen; 3000 con-
secutive transplant patients are currently registered, with 
transplantations performed back to 2004 [13].
Recipients ≥18 years of age who were registered in MATCH 
and who received a heart, lung, liver, or kidney transplanta-
tion between January 1, 2012, and September 1, 2016, were 
evaluated for inclusion. Combined SOTs were excluded. Only 
recipients who were anticipated to receive prophylaxis for 
at least 90  days were included, corresponding to CMV IgG 
seroconstellations of D+/R+, D+/R- and D-/R+ for kidney, 
heart, and lung recipients. Only D+/R+ and D+/R- were in-
cluded from the liver recipients; other seroconstellations are 
managed solely preemptively. Patients with incomplete med-
ical records and patients not starting prophylaxis within the 
first 14 days post-transplantation were also excluded (Figure 1). 
Approval from the regional ethics committee, Danish Data 
Protection Agency, and Danish Patient Safety Authority was ac-
quired before the study.
Data on Prophylaxis Administration
At our center, recipients of liver, heart, and lung transplanta-
tion generally receive 90  days of valganciclovir prophylaxis 
after transplantation with the standard dose of 900  mg daily 
(adjusted for their renal function), whereas the dose is set at 
450  mg every other day irrespective of estimated glomerular 
filtration rate (eGFR) for the recipients of kidney transplants. 
Inclusion of  patients
Exclusion
Included in MATCH
n = 3140
SOT
1/1/2012–1/9/2016
n = 830
Age ≥18 at SOT
n = 774
D+/R+, D+/R–,
D–/R+
serostatus
n = 613
Included in analysis
n = 585 
No breakthrough CMV
n = 547/585 (93.5%)
Do not stop prophylaxis
n = 550/585 (94.0%)
Stop prophylaxis
n = 35/585 (6.0%)
Breakthrough CMV
n = 38/585 (6.5%)
n = 28 do not start
prophylaxis
within 14 days and
censord at 14 days or earlier
n = 161
 D/R status not
 included or were 
D–/R+ liver transplants
n = 11 (missing DOB)
n = 45 age <18 y
n = 2310 not transplanted
within study period
Figure 1. Flowchart describing patient inclusion and exclusion in the study population (n = 585), as well as the number of people experiencing each study outcome. Thirty-
eight (6.5%) experienced prophylaxis breakthrough, and 35 (6.0%) stopped prophylaxis early. Abbreviations: BT, breakthrough; CMV, cytomegalovirus; DOB, date of birth; 
D/R, donor/recipient CMV IgG; MATCH, Management of Post-Transplant Infections in Collaborating Hospitals transplantation database; SOT, solid organ transplantation.
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Recipients were screened once a month with quantitative 
CMV polymerase chain reaction (PCR) or more frequently at 
the treating physician’s discretion. Data on CMV prophylaxis 
medication were collected from the date of transplantation 
and 90 (±7) days forward; other biochemical and clinical data 
were collected up to a year post-tx. Data on valganciclovir and 
ganciclovir dosage were recorded from a medical prescription 
database and were cross-referenced with clinical journals.
Prophylaxis Score Calculation
To compare prophylactic dosages between patients, a prophy-
laxis score for each patient was developed and calculated for 
each day within the prophylactic period (90±7 days) (Figure 2). 
Scores were calculated by dividing the actual dosage received by 
the manufacturers’ recommended doses (adjusted for eGFR) 
(Supplementary Figure 1), which will be referred to as the “op-
timal” dosage for the sake of simplicity: score = actual dose (mg)/
optimal dose (mg) ×100. We used the dose recommended by the 
manufacturers to maintain a universal standard as opposed to 
using local protocols. Optimal prophylaxis is thus a score of 100; 
a score of 200 would imply double the optimal dose and a score 
of 50 half the optimal dose. Optimal dosage was based on the 
patient’s recorded eGFR value (mL/min/1.73 m2; Chronic Kidney 
Disease Epidemiology Collaboration [CKD-EPI]) and weight (kg); 
eGFR values were used to determine the optimal dosage for both 
valganciclovir and ganciclovir; weight was only used to determine 
the optimal dosage for ganciclovir. Weight and eGFR were carried 
forward until the next available value so that a longitudinal data set 
was created for each day in the prophylaxis period. A sample score 
calculation can be found in Supplementary Figure 2.
For patients for whom records on body weight were missing, 
median weights were used; median weights were stratified by 
gender, age (<50 or ≥50  years), and transplant type (kidney, 
lung, heart, liver).
Outcome Measures and Definitions
The primary outcome in this study was CMV breakthrough 
during administration of prophylaxis. This event was defined 
as CMV infection during a period within the first 90 (±7) days 
post-transplantation, while the recipient was actively receiving 
CMV prophylaxis. The prevalence of CMV breakthrough 
during prophylaxis was stratified for D/R CMV IgG serostatus, 
age, and type of transplantation and was compared based on the 
various strata of prophylaxis scores.
We also investigated the prevalence of premature discontinu-
ation of prophylaxis and reasons for discontinuation. Premature 
prophylaxis discontinuation was defined as experiencing a dis-
continuation of prophylaxis for >7 days (prophylaxis score = 0 
for ≥7 consecutive days) after an active period of prophylaxis 
(having a score not equal to 0 for ≥1 day post-transplantation). 
Reasons for prophylaxis discontinuation were defined by those 
noted in medical records by attending physicians. Baseline 
(start of follow-up) was defined as the first day a patient receives 
prophylaxis (score ≠ 0) or day 14 post-transplantation.
CMV PCR
CMV was monitored through quantitative PCR assays using the 
COBAS AmpliPrep/COBAS TaqMan instrument. The conver-
sion factor for the instrument is 1 copy/mL to 0.91 IU/mL, with 
the lower quantification limit being 273 IU/mL. CMV infection 
Initiation Phase:
Tx Date
Initiation Phase
Day 14
A
Middle Phase
Day 83 Day 90
End phase
Demonstrating that a score has been calculated for
each day in the prophylactic period
Scorec =
Actual dose per day (mg)
Day
 70 Day
 71
Day
 72
Day
 73
Sco
re 7
3
Sco
re 7
2
Sco
re 7
1
Sco
re 7
0
Optimal dose per day (mg)
×100
Day 97
A and B A A
Prophylaxis must commence within the first 14 days post-tx.
Baseline for each patient is defined as the first date of  starting
prophylaxis or day 14 post-tx
End Phase:
Prophylaxis may terminate at any point in this period
Outcome A:
Prophylaxis breakthrougha
Outcome B:
Premature prophylaxis stopb [Only in the Middle Phase]
Figure 2. Illustration describing the prophylactic period, the calculation and interpretation of the score, and the definitions of the various outcomes in the study. The prophy-
lactic period is split into 3 phases. The score is the actual dose (mg) received divided by the optimal dose (mg) multiplied by 100. The 2 outcomes of the study are prophylaxis 
breakthrough and premature prophylaxis stop. aDefined as polymerase chain reaction–verified cytomegalovirus DNAemia in either plasma or bronchoalveolar lavage while 
actively receiving prophylaxis. bDefined as >7 consecutive days’ cessation of prophylaxis. cA score for each day within the patient’s prophylactic period has been calculated.
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was defined by either 2 consecutive CMV PCRs ≥273 IU/mL 
within 14 days of each other [14, 15] or 1 CMV PCR ≥2730 IU/
mL in plasma. Alternatively, fluid from a single bronchoalveolar 
lavage (BAL) with CMV PCR ≥2730 IU/mL was considered an 
infection [16]. Serostatus constellation (D/R) was defined by 
the combination of the donor and recipient CMV IgG statuses 
before transplantation.
Immunosuppression
A full description of the immunosuppressive regimen received 
by each transplantation group can be found in Supplementary 
Figure 3 [13].
Other Clinical Parameters
Clinical, demographic, and laboratory data on recipients, in-
cluding values for CMV PCR, eGFR, and other markers were 
collected longitudinally during the entire prophylactic period 
of the recipient from electronic health records. Leukopenia was 
defined as a white blood cell (WBC) count <3500 cells/mm3, 
and elevated liver enzymes were defined as alanine transami-
nase (ALT) >210 U/L for males and >135 U/L for females (ie, 
3× the upper limit of normal).
Statistical Analysis
Standard descriptive statistics were used to describe the cat-
egorical and continuous baseline clinical characteristics of 
the included patients. Patients were censored at death (as de-
fined by medical records), after a prophylaxis score  of  0 for 
≥7 consecutive days (premature prophylaxis stop), loss to fol-
low-up (last lab date +14 days), or re-transplantation within the 
90-day prophylactic period. Calculated prophylaxis scores were 
categorized as low (score < 90), medium (score = 90–≤190) and 
high (score  >  190). The lower boundary of 90 for a medium 
score was set just below the optimal score of 100; the medium 
score upper boundary of 190 was set just below an optimal treat-
ment dose (ie, double the optimal prophylaxis dose), namely a 
score of 200.
Kaplan-Meier estimates were used to illustrate time to pro-
phylaxis breakthrough and time to prophylaxis discontinua-
tion, stratified by transplant type and D/R seroconstellation. 
Univariate Cox analyses were performed to determine the 
impact of the prophylaxis score on prophylaxis breakthrough 
and premature prophylaxis discontinuation. Other explan-
atory covariates such as age, year of transplantation, type of 
transplantation, gender, eGFR post-transplantation, WBC 
count, liver enzyme levels (ALT), and D/R seroconstellation 
were also investigated. Variables included in the multivar-
iate analyses were based on significance values from univar-
iate analyses (P  <  .1). Cox analyses based on the cumulative 
time spent in each of the 3 scoring categories were performed, 
stratified for a priori selected risk factors, including trans-
plant type and D/R seroconstellation. Prophylaxis score, eGFR 
post-transplantation, WBC count, ALT levels, and cumulative 
time spent in each of the 3 scoring categories were included as 
time-updated variables. For modeling the score changes over 
time in figures, recipients were censored on the day of their first 
event (breakthrough or censoring as defined above); t tests were 
used to compare average scores at different time points.
Statistics were performed using SAS, version 9.4 (SAS 
Institute, Cary, NC). P values ≤.05 were considered significant.
RESULTS
Patient Characteristics
During the study period, 830 SOT recipients were transplanted. 
Of these, 245 patients were excluded (45 recipients <18 years old, 
11 missing birth dates, 161 either missing or seroconstellations 
other than D+/R+, D+/R- or D-/R+, and 28 did not start pro-
phylaxis within 14 days or were censored by day 14). The re-
maining 585 SOT recipients were included in the study, and of 
these, 311 (53.2%) were kidney transplants, 117 (20.0%) were 
liver transplants, 106 (18.1%) were lung transplants, and 51 
(8.7%) were heart transplants. With regards to seroconstellation, 
137 (23.4%) were D-/R+, 324 (55.4%) were D+/R+, and 124 
(21.2%) were D+/R- recipients. The median age at transplanta-
tion (interquartile range [IQR]) was 50.5 (40.9–58.9) years, with 
351/585 (60%) being male (Table 1).
Breakthrough on Primary Prophylaxis and Associated Risk Factors
Thirty-eight (6.5%; 95% confidence interval [CI], 4.5 to 8.5) 
recipients experienced breakthrough CMV infection during the 
90-day prophylactic period (Table 1). All 38 recipients experi-
enced CMV DNAemia in plasma; of these, 2 also experienced 
DNAemia in BAL within a week of infection diagnosis. Median 
time to infection from the start of follow-up (IQR) was 60 (45–
72) days, with the median CMV DNAemia load, defined as the 
first positive value preceding an infection, in plasma being 796 
(364–1592) IU/mL); 273 IU/mL is the lower limit of quantifica-
tion of the assay.
Of recipients with 1 year of follow-up (FU; 32/38 with break-
through), mutations in CMV UL97 (ie, genotypic resistance) de-
veloped in 9 of the recipients experiencing breakthrough (8/32, 
25.0%; 95% CI, 10.0 to 40.0); 2 recipients (2/32, 6.3%; 95% CI, 
–2.1 to 14.7) with prophylaxis breakthrough progressed to CMV 
disease (both CMV pneumonia) during the first year post-tx, 
both of whom were lung tx recipients. In contrast, among 
nonbreakthrough patients not censored for other reasons and 
with a year of FU, 108 (108/439, 24.6%; 95% CI, 20.6 to 28.6) 
experienced CMV DNAemia (ie, an infection after the prophy-
laxis period), of whom 3 (3/108, 2.8%; 95% CI, –0.31 to 5.91) 
developed resistance. Additionally, among the 108 patients 
experiencing CMV DNAemia, 30 (30/108, 27.8%; 95% CI, 19.4 
to 36.2) progressed to CMV disease (of whom 18 were CMV 
pneumonia, 8 CMV syndrome, and 4 gastrointestinal [GI] tract 
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disease) within the first year post-tx. This resulted in an overall 
viral resistance rate of 8.4% (12/143; 95% CI, 3.8 to 12.9) among 
those recipients in the cohort experiencing DNAemia not 
censored for other reasons and with a year of FU. Of recipients 
with a minimum of 1 day with a score <90, the median score 
for recipients within the defined follow-up in the first 90 (±7) 
days post-tx with prophylaxis breakthrough vs those without 
breakthrough (IQR) was 50 (50–100) and 100 (50–100), respec-
tively. The median score for the 7 days preceding the diagnosis 
of the breakthrough infection (IQR) was 50 (50–100; n = 38). At 
2 weeks (day 15) post-tx, differences in the mean score for those 
that went on to experience breakthrough (78.7; n = 34) vs those 
who did not experience breakthrough (100.3; n = 537) were sig-
nificant (P < .01). Differences in the mean score after 1 month 
(28 days) were also significant (P < .01). A visual representation 
of the changes in score over time can be seen in Figure 3.
Recipients with a D+/R- serostatus constellation were sig-
nificantly more likely to develop a breakthrough infection 
compared with recipients with a D+/R+ or D-/R+ serostatus 
constellation (16.1% vs 4.6% and 2.2%; P  <  .01) (Figure 4A). 
Differences were also noted in prophylaxis breakthrough rates 
between different organ types, with kidney and lung trans-
plant recipients having increased rates of breakthrough (8.7% 
and 6.6%) as compared with liver (2.6%) and heart transplant 
(2.0%) recipients (P = .067). Gender, year of transplant, and age 
were not noted to be significantly different among recipients 
with and without breakthrough (Table 1).
Without adjusting for covariates, for every 10% more time 
spent during the defined follow-up with a score <90, the risk of a 
breakthrough infection increased by 15% (hazard ratio [HR], 1.15; 
95% CI, 1.07 to 1.24; P < .01). This finding was confirmed in the 
multivariate analysis: Having adjusted for D/R seroconstellation, 
transplant type, and death as a competing risk factor, every 10% 
of additional follow-up time spent with a score <90 was associ-
ated with a 15.7% increased risk of breakthrough (adjusted HR 
[aHR], 1.16; 95% CI, 1.04 to 1.29; P = .01). This implies that the 
adjusted incidence rate ratio of CMV breakthrough is almost 
double (aHR, 1.98; 95% CI, 1.19 to 3.63; P <  .01) in recipients 
spending 50% more follow-up time with a score <90 (Figure 
5). When adjusting for type of transplant and score, a D+/R- 
serostatus constellation was also deemed to be an independent 
risk factor for developing CMV prophylaxis breakthrough (aHR, 
5.37; 95% CI, 2.63 to 10.98; P < .001). Tx type was not significant, 
and no relevant interactions were observed.
Premature Prophylaxis Discontinuation
In the study population, 35 (6.0%; 95% CI, 4.1 to 7.9) recipients 
experienced a premature cessation of prophylaxis during the first 
90 (±7) days post-transplantation for reasons other than emerging 
CMV infection, of whom 25 were lung tx recipients (n = 25/35, 
71%; 95% CI, 56 to 86). The median time to premature discon-
tinuation among those who discontinued prophylaxis (IQR) 
was 29 (18–63) days from the start of follow-up. Lung trans-
plant recipients were more likely than liver, kidney, and heart 
transplant recipients to discontinue prophylaxis early (23.6% vs 
3.4%, 1.9%, and 0% respectively; P < .001) (Figure 4B). Of lung tx 
recipients discontinuing prophylaxis prematurely and with a year 
of FU, 14 (14/25, 56.0%; 95% CI, 36.5 to 75.5) experienced CMV 
DNAemia (ie, infection) and 5 (5/25, 20.0%; 95% CI, 4.32 to 35.7) 
progressed to CMV disease (4 with CMV pneumonia, 1 with GI 
Table 1. Baseline Characteristics of 585 SOT Patients, Stratified for Breakthrough Infections and Prophylaxis Discontinuation
 Characteristic All Recipients
No Breakthrough 
Infection
Breakthrough  
Infection P Value
No Stop in  
Prophylaxis
Stop in  
Prophylaxis P Value
 All 585 (100.0) 547 (93.5) 38 (6.5)  550 (94.0) 35 (6.0)  
Tx type, No. (%) Heart 51 (8.7) 50 (98.0) 1 (2.0) .067 51 (100.0) 0 (0.0)  <.001
 Kidney 311 (53.2) 284 (91.3) 27 (8.7)  305 (98.1) 6 (1.9)  
 Liver 117 (20.0) 114 (97.4) 3 (2.6)  113 (96.6) 4 (3.4)  
 Lung 106 (18.1) 99 (93.4) 7 (6.6)  81 (76.4) 25 (23.6)  
Gender, No. (%) Male 351 (60.0) 327 (93.2) 24 (6.8) .681 329 (93.7) 22 (6.3) .722
Year tx, No. (%) 2012 130 (22.2) 122 (93.9) 8 (6.1) .613 117 (90.0) 13 (10.0) .022
 2013 98 (16.8) 94 (95.9) 4 (4.1)  90 (91.8) 8 (8.2)  
 2014 132 (22.6) 125 (94.7) 7 (5.3)  129 (97.7) 3 (2.3)  
 2015 142 (24.3) 130 (91.6) 12 (8.4)  132 (93.0) 10 (7.0)  
 2016 83 (14.2) 76 (91.6) 7 (8.4)  82 (98.8) 1 (1.2)  
D/R status, No. (%) D-/R+ 137 (23.4) 134 (97.8) 3 (2.2)  <.001 120 (87.6) 17 (12.4) .001
 D+/R+ 324 (55.4) 309 (95.4) 15 (4.6)  310 (95.7) 14 (4.3)  
 D+/R- 124 (21.2) 104 (83.9) 20 (16.1)  120 (96.8) 4 (3.2)  
Median age (IQR), y  50.5 (40.9–58.9) 50.8 (41.1–58.9) 48.2 (35.5–59.4) .445 50.4 (40.6–58.8) 50.9 (44.7–59.3) .34
Prior transplant, No. (%) 23 (3.9) 23 (4.2) 0 (0.0) .197 13 (8–80) 86 (45–90)  <.001
Median weight on day 1a (IQR), kg 74 (61–85) 74 (64–83) 71 (61–83) .399 74.8 (63.5–82.5) 68 (60–73) .01
Abbreviations: D/R, donor/recipient; IQR, interquartile range; SOT, solid organ transplantation.
aThree hundred sixty-eight out of 585 patients had available weight post-transplant.
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tract disease). Additionally, premature prophylaxis discontinu-
ation rates were significantly different depending on D/R CMV 
IgG serostatus constellation; 12.4% (95% CI, 6.9 to 17.9) of D-/R+ 
recipients experienced a stop in prophylaxis compared with 4.3% 
(95% CI, 2.1 to 6.5) and 3.2% (95% CI, 0.1 to 6.3) of D+/R+ and 
D+/R- recipients, respectively (P = .001).
The main risk factor for prophylaxis discontinuation was 
lung transplantation (HR, 20.2; 95% CI, 3.34 to 121.9; P = .001), 
adjusted for year of transplantation, donor/recipient CMV IgG 
seroconstellation, time spent with a score  >190, WBC count, 
liver enzyme levels (ALT), eGFR, and death as a competing risk 
factor. D-/R+ seroconstellation was also an independent risk 
factor for prophylaxis discontinuation (aHR, 3.57; 95% CI, 1.55 
to 8.20; P = .003). Age and gender did not differ significantly in 
those with premature prophylaxis cessation vs those without.
Reasons for Premature Discontinuation of Prophylaxis
The main reasons for premature discontinuation of prophy-
laxis were liver toxicity (n  =  10), patient- and/or physician-
related reasons (n = 12), and myelosuppression (n = 6) (Table 
2). Fifty-three percent of lung tx recipients experienced leuko-
penia during the first 90  days post-transplant. This contrasts 
with 47%, 17%, and 41% for heart, kidney, and liver transplant 
recipients, respectively (P  <  .01). Current leukopenia (aHR, 
4.10; 95% CI, 1.13 to 14.9; P = .03) was predictive of prophylaxis 
discontinuation; it was also predictive of discontinuing prophy-
laxis 14 days later (aHR, 3.94; 95% CI, 1.10 to 14.14; P = .04). 
Elevated ALT levels were not significant in either time range. 
Higher doses of (val)ganciclovir were not significantly associ-
ated with increased rates of leukopenia or elevated ALT levels.
DISCUSSION
In this study, we introduced a novel and simple method for 
evaluating the optimal dosage for universal prophylaxis. Using 
this method, our data demonstrate that recipients receiving 
prophylaxis in dosages below the recommendations of the 
manufacturers (adjusted for eGFR) are at an increased hazard of 
subsequent CMV prophylaxis breakthrough, particularly if the 
recipients had CMV IgG D+/R- mismatch. Furthermore, 25% 
of the lung transplant recipients discontinued prophylaxis be-
fore day 90, mainly because of toxicity. Our results highlight the 
importance of adjusting the administered dosage of prophylaxis 
according to the current eGFR, as well as the continued need for 
newer and less toxic agents against CMV.
In line with the manufacturers’ recommendations, the cur-
rent guidelines recommend 900 mg of valganciclovir daily for 
universal prophylaxis after SOT [2, 3, 5]. However, several re-
cent studies suggest an equivalent efficacy with a lower dose 
(450 mg for valganciclovir) [6, 12]. An important difference is 
that these studies used CMV disease and not CMV DNAemia 
as the primary end point. However, progression to CMV dis-
ease is largely preventable (apart from certain subpopulations 
experiencing pneumonia, retinitis, and GI tract disease due to 
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Figure 3. Graphs illustrating the changes in score over time between days 15 and 89 and the last 14 days before the first event (breakthrough, censoring) experienced by 
recipients, stratified by breakthrough status. Graphs over time for only kidney transplant recipients are also included. Patients without prophylaxis breakthrough had visibly 
higher scores over time than recipients experiencing breakthrough. Abbreviations: BT, breakthrough; No BT, no breakthrough; SOT, solid organ transplantation.
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low or undetectable plasma viral loads), as it is a downstream 
effect of insufficient treatment of CMV DNAemia. Proper 
screening programs and preemptive intensification of treatment 
in case of breakthrough infection while on prophylaxis can to 
a large extent prevent this progression to CMV disease from 
CMV DNAemia [16–18]. Similar to our observations, a study 
by Stevens et  al. [9] that looked at prophylaxis breakthrough 
rates among kidney recipients found low-dose valganciclovir, 
defined as 450 mg daily (adjusted for renal function), to be sub-
optimal in preventing prophylaxis breakthrough in the first 
6 months post-tx. The kidney transplant department at our in-
stitution has subsequently increased their prophylactic dosages. 
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Figure 4. A, Kaplan-Meier curve depicting the time to prophylaxis breakthrough stratified by seroconstellation within the first 90 days post-transplantation. Donor (D)+/
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Additionally, recipients with a D+/R- CMV IgG mismatch 
were at a significantly higher risk of prophylaxis breakthrough, 
highlighting the continued need to monitor this recipient pop-
ulation closely.
As far as we know, this study is the first to evaluate the effect 
of longitudinally collected (val)ganciclovir dosages on CMV 
prophylaxis breakthrough rates by taking changes in eGFR, 
dosages, and frequency of administration into account using a 
score. Clinically, such a scoring system could be a useful clinical 
tool determined in real time to assist the clinician in ensuring 
that recipients are getting an optimal level of prophylaxis.
Rates of viral resistance among SOTs having experienced vi-
remia are usually between 5% and 12% [3, 19, 20], in concur-
rence with our results. Viral resistance to ganciclovir poses a 
major issue clinically, as patients who later develop CMV dis-
ease due to resistant CMV have poorer clinical outcomes [21, 
22]. Additionally, the treatment of CMV infections in these 
patients is problematic [19, 21, 23]. Presently, recommended al-
ternative therapies include foscarnet and a reduction in immu-
nosuppression, although no controlled trials have definitively 
confirmed this [3, 19]. Striking a balance between adequate 
treatment dosages and avoiding treatment-limiting adverse 
effects remains difficult. As such, the potential addition of new 
drugs [24–26] and vaccines [27] to the CMV treatment arsenal 
is welcomed.
The premature discontinuation of prophylaxis rate due to 
adverse events was high in lung transplant recipients, fur-
ther highlighting the vulnerability in this group. In a study by 
Table 2. Reasons for Prophylaxis Discontinuation by Solid Organ Transplantation Type
Reason for Discontinuation
SOT
Heart Lung Kidney Liver Total
Liver-related 0 9 1 0 10
Kidney-related 0 3 0 0 3
Liver- and kidney-related 0 1 0 0 1
Patient- and/or physician-relateda 0 7 2 3 12
Subsitute medication receivedb 0 0 0 1 1
Myelosuppression 0 5 1 0 6
Skin irritation 0 0 1 0 1
Fecal issues 0 0 1 0 1
Total 0 25 6 4 35
Abbreviation: SOT, solid organ transplantation.
aMisunderstanding or unknown reason for stop.
bValaciclovir.
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Figure 5. Graph showing the adjusted incidence rate ratio of cytomegalovirus (CMV) breakthrough with increasing follow-up time (FUT) with <90% optimal CMV prophy-
laxis. Recipients spending 50% more follow-up time with a score <90 were almost twice as likely to experience prophylaxis breakthrough. A score of 100 was defined as 
optimal; a score <90 (ie, 90% of optimal prophylaxis) would thus be suboptimal. A 10% increase in cumulative follow-up time with a score <90 would entail a patient having 
a 10% increase in the number of days where their score had a value <90. For example, if a patient’s FUT time was 90 days, a 10% increased cumulative FUT would be 9 more 
days with a score <90. aBaseline was defined as the first day of starting prophylaxis or day 14 post-transplant. Abbreviation: CI, confidence interval.
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Wiita et al., in which recipients received indefinite lengths of 
prophylaxis, 50.8% of recipients had to discontinue prophy-
laxis primarily due to leukopenia, albeit at a median time of 
8 months post-tx [28]. Similarly, in a study by Zamora, 32% of 
lung transplant recipients receiving valganciclovir prophylaxis 
required discontinuation due to leukopenia and neutropenia 
[29]. The rate of discontinuation among our lung transplant 
recipients was high relative to that observed in liver, kidney, 
and heart SOTs. However, differences in the rate of such 
events alone probably do not explain the stark differences 
in prophylaxis discontinuation rates. Although lung trans-
plant recipients may be at an increased risk of certain ad-
verse events, lung transplant clinicians at our institution are 
probably also more prone to reacting to adverse changes in 
recipient biochemistry. Differences in immunosuppression, 
particularly the use of ATG and anti-infective prophylaxis (eg, 
voriconazole) in certain subpopulations, could also explain 
such differences; subsequently, voriconazole is no longer part 
of the standard prophylaxis regimen at the lung transplant 
department. Variability in clinical judgement was likely also 
contributing, and this is supported by the evidence that D-/
R+ SOT recipients are significantly more likely to stop pro-
phylaxis early; in these low-risk recipients, clinicians may be 
more inclined to discontinue prophylaxis in the presence of 
leukopenia.
This study has some limitations. This is a single-center study, 
where several different SOTs have been included to increase 
statistical power. This may have introduced some heteroge-
neity to the data. However, all analyses were stratified for the 
type of transplantation. Furthermore, the data collection on 
administered anti-CMV drugs was performed retrospectively, 
which has inherent weaknesses. Adherence to prophylaxis is 
assumed and has not been quantified; this may influence the 
incidence of CMV breakthrough infections. CKD-EPI was used 
to measure renal function (as per institutional protocols), as 
opposed to Cockroft-Gault, which is used in manufacturers’ 
recommendations. Exact immunosuppression doses for each 
patient were not collected but will be investigated in future 
studies.
Despite this, the strengths of this study include the large size 
of the cohort and the precision of the data. Data points for CMV 
medication and other relevant lab values were tracked on a day-
by-day basis, allowing changes in medication and recipient bio-
chemistry to be considered using the score; the simplicity of the 
score is a major strength, as is the use of a longitudinal rather 
than cross-sectional approach. Additionally, data regarding 
CMV prophylaxis were collected by a single person, preventing 
interobserver variability in data collection.
In conclusion, recipients receiving prophylactic dosages 
below those recommended by the manufacturers are at an 
increased risk of experiencing prophylaxis breakthrough. This 
suggests that low-dose prophylactic regimens are suboptimal 
in preventing CMV breakthrough in solid organ transplant 
recipients and highlights the importance of dose adjustment 
to the latest renal function value (eGFR). The high rate of pre-
mature prophylaxis discontinuation, particularly among lung 
transplant recipients, also justifies the urgent need for novel, 
less toxic drugs.
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